Clinical Trials
469
Active:13
Completed:254
Trial Phases
6 Phases
Early Phase 1:16
Phase 1:41
Phase 2:38
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (388 trials with phase data)• Click on a phase to view related trials
Not Applicable
236 (60.8%)Phase 1
41 (10.6%)Phase 2
38 (9.8%)Phase 4
30 (7.7%)Phase 3
27 (7.0%)Early Phase 1
16 (4.1%)Amino Acid Infusion in Cardiac Surgery
Phase 4
Not yet recruiting
- Conditions
- Acute Kidney InjuryCardiac Surgery
- Interventions
- Drug: Travesol 10%
- First Posted Date
- 2025-06-22
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 130
- Registration Number
- NCT07030933
CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy
Phase 1
Not yet recruiting
- Conditions
- Chemotherapy-Induced Peripheral Neuropathy
- Interventions
- Drug: CBG/CBD Oil
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT07016971
- Locations
- 🇺🇸
Penn State Cancer Institute, Hershey, Pennsylvania, United States
Mitigating Burnout in Nursing and Associated Healthcare Staff
Not Applicable
Not yet recruiting
- Conditions
- Burn OutNurses
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 300
- Registration Number
- NCT07018609
Influence of Standardized Perioperative Anesthetic, Analgesic Care on Outcome of Patients Undergoing Hip Fracture Surgeries
Phase 1
Not yet recruiting
- Conditions
- Nerve BlockFractures, HipLocal AnesthesiaGeriatric
- Interventions
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT06925789
Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
Phase 2
Not yet recruiting
- Conditions
- Graft-versus-Host Disease (GVHD)Allogeneic Stem Cell TransplantationHematologic Malignancies
- Interventions
- Drug: Cyclophosphamide (primary intervention for GVHD prophylaxis)
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT06926595
- Locations
- 🇺🇸
Penn State Cancer Institute, Hershey, Pennsylvania, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 94
- Next
News
No news found